Challenges and Possibilities of Cell-Based Tissue-Engineered Vascular Grafts
Open Access
- 18 February 2021
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Thinking Skills and Creativity
- Vol. 2021, 1532103
- https://doi.org/10.34133/2021/1532103
Abstract
There is urgent demand for biologically compatible vascular grafts for both adult and pediatric patients. The utility of conventional nonbiodegradable materials is limited because of their thrombogenicity and inability to grow, while autologous vascular grafts involve considerable disadvantages, including the invasive procedures required to obtain these healthy vessels from patients and insufficient availability in patients with systemic atherosclerosis. All of these issues could be overcome by tissue-engineered vascular grafts (TEVGs). A large body of evidence has recently emerged in support of TEVG technologies, introducing diverse cell sources (e.g., somatic cells and stem cells) and novel fabrication methods (e.g., scaffold-guided and self-assembled approaches). Before TEVG can be applied in a clinical setting, however, several aspects of the technology must be improved, such as the feasibility of obtaining cells, their biocompatibility and mechanical properties, and the time needed for fabrication, while the safety of supplemented materials, the patency and nonthrombogenicity of TEVGs, their growth potential, and the long-term influence of implanted TEVGs in the body must be assessed. Although recent advances in TEVG fabrication have yielded promising results, more research is needed to achieve the most feasible methods for generating optimal TEVGs. This article reviews multiple aspects of TEVG fabrication, including mechanical requirements, extracellular matrix components, cell sources, and tissue engineering approaches. The potential of periodic hydrostatic pressurization in the production of scaffold-free TEVGs with optimal elasticity and stiffness is also discussed. In the future, the integration of multiple technologies is expected to enable improved TEVG performance.Keywords
Funding Information
- Japan Agency for Medical Research and Development (19ek0109240h003, 19lm0203087h0001)
- Japan Society for the Promotion of Science (JP20K20987, JP19H00749, JP15H05761, JP17K19403, JP18K08767, JP20K21638, JP20H03650, JP16H07107, JP18K15681)
This publication has 128 references indexed in Scilit:
- Recent Developments in Myofibroblast Biology: Paradigms for Connective Tissue RemodelingThe American Journal of Pathology, 2012
- Generation of human vascular smooth muscle subtypes provides insight into embryological origin–dependent disease susceptibilityNature Biotechnology, 2012
- Tissue-engineered vascular graft remodeling in a growing lamb model: expression of matrix metalloproteinasesEuropean Journal of Cardio-Thoracic Surgery, 2011
- An overview of tissue and whole organ decellularization processesBiomaterials, 2011
- Hydrostatic pressure independently increases elastin and collagen co‐expression in small‐diameter engineered arterial constructsJournal of Biomedical Materials Research Part A, 2011
- Pericyte-based human tissue engineered vascular graftsBiomaterials, 2010
- A bilayered elastomeric scaffold for tissue engineering of small diameter vascular graftsActa Biomaterialia, 2010
- Scaffold-free vascular tissue engineering using bioprintingBiomaterials, 2009
- Mechanical properties of completely autologous human tissue engineered blood vessels compared to human saphenous vein and mammary arteryBiomaterials, 2009
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002